NCT05888870View on ClinicalTrials.gov

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

PHASE4RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Hemophilia A With Inhibitor
Interventions
DRUG

SCT800 and Daratumumab

SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times

DRUG

SCT800

SCT800 50IU/kg TIW alone

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

All Listed Sponsors
collaborator

Sinocelltech Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER